Play all audios:
Access through your institution Buy or subscribe The survival outcomes of patients with relapsed and/or refractory mantle-cell lymphoma (MCL) after receiving BTK inhibitors are poor;
therefore, new treatment options are needed for these patients. Chimeric antigen receptor (CAR) T cell therapies targeting CD19 have demonstrated efficacy in several subtypes of B cell
lymphomas, although limited results in patients with MCL have been reported. Now data from the ZUMA-2 trial reveal promising activity of the anti-CD19 CAR T cell product KTE-X19 against MCL.
In ZUMA-2, KTE-X19 was successfully manufactured for 71 of 74 patients with relapsed and/or refractory MCL. A high content of leukaemic blasts in peripheral blood has been proposed as the
cause of failed manufacturing of CAR T cells because it results in proportionally low numbers of non-exhausted T cells in the starting cell population. During the manufacturing of KTE-X19,
circulating CD19+ malignant cells were removed in order to address this issue by reducing the potential activation and exhaustion of anti-CD19 CAR T cells in the ex vivo portion of the
process. This is a preview of subscription content, access via your institution ACCESS OPTIONS Access through your institution Access Nature and 54 other Nature Portfolio journals Get
Nature+, our best-value online-access subscription $29.99 / 30 days cancel any time Learn more Subscribe to this journal Receive 12 print issues and online access $209.00 per year only
$17.42 per issue Learn more Buy this article * Purchase on SpringerLink * Instant access to full article PDF Buy now Prices may be subject to local taxes which are calculated during checkout
ADDITIONAL ACCESS OPTIONS: * Log in * Learn about institutional subscriptions * Read our FAQs * Contact customer support REFERENCES ORIGINAL ARTICLE * Wang, M. et al. KTE-X19 CAR T-cell
therapy in relapsed or refractory mantle-cell lymphoma. _N. Engl. J. Med._ 383, 1331–1342 (2020) Article Google Scholar Download references AUTHOR INFORMATION AUTHORS AND AFFILIATIONS *
Nature Reviews Clinical Oncology http://www.nature.com/nrclinonc Diana Romero Authors * Diana Romero View author publications You can also search for this author inPubMed Google Scholar
CORRESPONDING AUTHOR Correspondence to Diana Romero. RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Romero, D. KTE-X19 active in MCL. _Nat Rev Clin
Oncol_ 17, 336 (2020). https://doi.org/10.1038/s41571-020-0373-3 Download citation * Published: 21 April 2020 * Issue Date: June 2020 * DOI: https://doi.org/10.1038/s41571-020-0373-3 SHARE
THIS ARTICLE Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to
clipboard Provided by the Springer Nature SharedIt content-sharing initiative